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ABSTRACT
The antibiotic distamycin A is a DNA minor groove
binding drug (MGB) that recognizes a stretch of a least
four ATs. The alkylating benzoyl mustard derivative
tallimustine (FCE 24517) has powerfull anti-tumor
activity. Using the electrophoretic mobility shift assay
(EMSA) we determined that both compounds can
prevent binding of TBP and, with 10-fold higher
concentration, TBP-TFIIA (DA) and TBP-TFIIA-TFIIB
(DAB) to a TATA box. Once formed, the DA and DAB
complexes are more resistant to MGB challenge. Both
drugs can inhibit basal in vitro transcription of a
minimal TATA-containing promoter and similar con-
centrations are necessary for binding and transcrip-
tional inhibition. Tallimustine shows strong selectivity
by decreasing only correctly initiated transcripts. Even
at high doses (20 gM), however, they cannot disturb a
competent pre-initiation complex or Pol 11 progression.
This functional in vitro model will provide a way to
investigate the activity of sequence-specific DNA
binding drugs with potential anti-viral and anti-tumour
activity and to develop novel more selective com-
pounds.
INTRODUCTION
Distamycin A is a sequence-specific DNA binding compound
which recognizes AT-rich stretches by interacting non-covalently
with the minor groove of B-DNA and replacing the spine of
hydration (1,2).
Co-crystals with selected oligonucleotides identified the details
of these interactions (3,4). Sequence selectivity arises from steric
hindrance of the exocyclic C2 amino group of the guanine and by
van der Walls interactions in the narrower minor groove
associated with AT pairs (4). It also distorts DNA by inducing
conformational changes in the flanking sequences (3).
Unlike distamycin A, alkylating derivatives have shown
powerful anti-tumor activity (6-8). One such minor groove
binder (MGB) is tallimustine, a benzoyl nitrogen mustard that has
additional sequence-specific requirements for DNA alkylation
(8,9). Distamycin A has been shown to interfere with the activity
of topoisomerase I (10), topoisomerase II (11) and DNA
polymerases (12), as well as the binding of structural proteins
such as histone H I with AT-rich SAR sequences (13) and HMG- 1
to satellite DNA (14). The exact mechanisms by which these
compounds exert their action in vivo are still elusive; in particular
it is not clear why tallimustine, but not distamycin A, has
anti-tumor activity.
One of the possibilities is that they might regulate gene
expression by altering the binding of important regulatory
proteins to their natural target sequences. Indeed, recent studies
indicate that MGBs are able to inhibit binding of several
transcription factors that recognize specific AT-rich sequences,
including Gatal, Octa (15), Antennapedia, Ftz (16) and TBP
(17). The latter observation is of particular importance, given the
pivotal role that TBP has in the mechanisms of transcriptional
activation. However, the actual influence of these compounds on
the transcription processes has yet to be tested.
The AT-rich stretch known as the TATA box is the most
common element in eukaryotic Pol II promoters (18) and plays
a key role in regulating the overall level of transcription and in
positioning the initiation start site (19,20).
It is usually located between -25 and -30 bp upstream of the
initiation start site and appears to bind a single DNA binding
protein, TBP, whose gene has been cloned from different species;
protein sequence alignments clearly identified the C-terminal 180
amino acids as an extremely conserved domain, encoding the
DNA binding part of the protein.
Crystallographic studies of yeast and Arabidopsis thaliana
TBP, alone or in combination with TATA sequences, have shown
a saddle-like structure that binds by making contacts through a
concave surface with the minor groove of the DNA (21-24). In
addition, TBP is able to significantly bend the double helix
towards the major groove by an angle of 80°, resulting in a
remarkable widening and flattening of the minor groove (23-24).
Biochemical and in vitro transcription studies indicate that TBP
is associated with other polypeptides as part of the multi-subunit
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TFIID complex (25), which nucleates the initial events in the
ordered assembly of the pre-initiation complex, involving other
general transcription factors: THIA, -JIB, -1IE, -11F, -JIG, -IIH
and Pol 11 (26,27).
A number of reasons thus lead us to postulate that MGBs could
interfere with transcription by inhibiting TBP binding. To test this
hypothesis we used the electrophoretic mobility shift assay
(EMSA) with recombinant human and yeast TBP, purified TFIIA
and recombinant TFIIB for in vitro binding studies and a sensitive
TBP-dependent in vitro transcription system for functional
experiments.
MATERIALS AND METHODS
Drugs and protein purifications
Distamycin A was dissolved in DMSO at a 10 mM stock
concentration; tallimustine was dissolved inDMF at 5 mM. Stock
solutions were kept at -20'C and freshly diluted in H20 shortly
before use.
Recombinant yeast and human TBP (yTBP and hTBP) were
produced in Escherichia coli from the T7 expression vector and
purified as previously described (28); production and purification
of recombinant human T'lFB was as previously described (29).
TFIIA was purified through heparin Ultrogel, DEAE, Phe-
nylSPW and HAP.t31 columns (30).
For the experiments shown in Figure 3, hTBP was produced
from inclusion bodies, according to the described method (31):
inclusion bodies were resuspended in 6 M GnCI and slowly
dialyzed at 4°C against NDB buffer (20% glycerol, 20 mM
HEPES, pH 7.9, 100 mM KCl, 0.5 mM EDTA, 1 mM dTT) over
a period of 4 h. The resulting material was centrifuged in a
Eppendorf centrifuge for 10 min and the supernatant stored in
liquid nitrogen. Under these conditions TBP was at least 80%
pure.
EMSA
Binding reactions were performed with a 37mer containing the
AdML TATA box (GAAGGGGGTATAAAAGGGGGTGGGG-
GCGTTCGTCCT); 0.1 ng end-labeled oligonucleotide was
incubated with 1-5 ng (2-10 nM) yTBP or 0.2-0.5 jg hTBP in
8% glycerol, 2% PEG 6000, 10mM HEPES, pH 7.9,50mM KCl,
5 mM ammonium sulfate, 5 mM MgCl2, 0.2 mM EDTA, 5 mM
dTT in a final volume of 15 gl. After 30 min at 30°C, samples
were loaded on a 5% 0.5x TBE gel containing 2 mM MgCl2, 5%
glycerol, 1 mM dTT and run in a 0.5 TBE/2 mM MgCl2 buffer
for 3 h. The gels were dried and exposed to Kodak XAR films.
When indicated, 0.5 gl partially purified TFIIA and 20 ng
recombinant TFIIB were used. EMSA for the DAB complex
were performed in acrylamide gels without MgCl2 and dTT.
EMSA experiments in which the SP1 binding oligonucleotide
was used (GATCCCCCGCCCC) were performed with 5 jg
K562 nuclear extracts in 5% glycerol, 50 mM KCl, 20 mM
HEPES, pH 7.9,5 mM MgCl2, 1 mM dTT.
In vitro transcription
The DNA template used for in vitro transcriptions was pAL5 (32).
Briefly, it contains the rabbit ,-globin first exon and promoter
sequences up to position -41 (AGGACTTGGGCATAAAAGG-
CAGAGCAGGGCAGCTGCTGCT +1).
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Figure 1. Effect ofMGBs on SPI binding. Increasing concentrations ofMGBs
were pre-incubated with an SPI binding oligonucleotide, before addition of
K562 nuclear extracts and EMSA analysis. Bands corresponding to specific
SPI complexes are indicated.
The preparation of nuclear extracts from exponentially grow-
ing K562 cells, the in vitro transcription reactions and RNA
purification procedures were performed exactly as previously
detailed (33). In all reactions 4 g1 extract and 50 ng template DNA
were used. S1 mapping analysis was done as described (34), using
a single-stranded DNA probe that, upon hybridization with
pAL5-transcribed RNA, generates a 60 bp fragment correspon-
ding to the correct +1 3-globin signal and a 70 bp fragment
corresponding to read-through (RT) transcripts (see 30-32).
RESULTS
MGBs inhibit TBP-TATA interactions
As a first step to understand a possible role ofMGBs in regulating
transcription, we set up experiments to verify the specificity of
MGB compounds. First we used the electrophoretic mobility shift
assay (EMSA) to test whether binding of these drugs was able to
inhibit DNA binding proteins that do not recognize AT-rich
sequences. For this purpose SPJ was a logical candidate, since it
is known to recognize GC-rich sequences (35). Figure 1 shows
that the binding of SPI to DNA is completely unaffected by
pretreatment of the target oligonucleotide with dystamicin A or
tallimustine, even at high concentrations.
A second control experiment was performed to see whether
MGBs would stably bind to recombinant TBP, thus possibly
altering normal protein-protein interactions of TBP with natural
partners such as TFIIA or with the target TATA sequence. TFIIA
is a heteromeric positive regulator of transcription which has no
intrinsic capacity to bind DNA (36-38): the TBP-TFIIA-TATA
(DA) complex can be visualized in EMSA and was shown to be
specific and to contain TBP, both by competition analysis with
unlabeled TATA-containing oligonucleotides and by anti-TBP
antibody challange (not shown; see 28-30).
We incubated different concentrations of hTBP with distamy-
cin or tallimustine at a high (20 gM) concentration and
subsequently, after dialysis to remove the two drugs, with TFIIA
and an oligonucleotide containing a high affinity binding site for
TBP (39-41): if stable interactions or modifications of TBP
occurred, one would expect a severe decrease in formation of the
DA complex resulting from the association of TBP with TFIIA
and the TATA box. Results shown in Figure 2 show no significant
variation in the ability of distamicin A- or tallimustine-treated
hTBP to interact with TFIIA and DNA, compared with untreated
controls, over three TBP concentrations. Thus there is no direct
adverse effect ofMGBs onTBP stability, conformation or affinity
for DNA.
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Figure 2. Effect of MGBs on TBP and TFIIA proteins. MGBs were
pre-incubated at a 20 jiM concentration with increasing amounts of hTBP for
15 min at 30'C and then removed by dialysis at4C for 30 min. TBPs were then
added to binding reactions containing TFIIA and an AdML TATA oligonucleo-
tide and run on EMSA. The DA complex is indicated.
We therefore started to analyze possible inhibitory effects ofthe
two drugs on binding of Saccharomyces cerevisiae and human
recombinant TBP to the TATA oligonucleotide employed above:
the oligonucleotide is exclusively GC-rich and hence not a target
for these drugs, aside from the central TATAAAA (39-41). When
incubated with 1-5 ng (2-5 nM) yTBP alone, the labeled TATA
oligonucleotide formed a retarded complex (Fig. 3A, lane 1); this
band is specific, since it can be competed by an excess of
wild-type cold oligonucleotide, but not by an oligonucleotide
mutated in the TATA box (data not shown; see 28). It should be
noted that under these conditions the free oligonucleotide is
always in excess with respect to the recombinant protein, no more
than 20% being complexed and shifted by TBP.
When we pre-incubated the labeled oligonucleotide with
increasing concentrations (20 nM-20 gM) of distamycin A and
the alkylating derivative tallimustine before addition of recombi-
nant yTBP we observed a clear decrease in TBP-TATA complex
formation at 2 ,uM (Fig. 3A, lanes 2-9). In parallel experiments
we changed the order of addition, by pre-incubating the
recombinant protein with the DNA before addition of the drugs.
Results of the latter experiments were very similar (Fig. 3B, lanes
1-9) to the one reported in Figure 3A. Tallimustine appears to be
slightly less efficient (2-fold) than distamycin A (compare lanes
4 and 8 in Fig. 3A and B).
We next tested recombinant hTBP in the EMSA under the same
experimental conditions. Compared with yTBP, a higher hTBP
concentration (100- to 500-fold) was necessary to detect a
retarded band (28-30). Inhibition was already evident at 200 nM
and was complete at 2 ,uM (Fig. 3C, lanes 1-10). Essentially
identical results were obtained inverting the order of addition,
namely pre-incubating the target oligonucleotide with hTBP first
(not shown). With respect to yTBP, hTBP was thus more
susceptible to MGB interference. Taken together, these experi-
ments indicate thatMGB drugs can either inhibit or displace TBP
binding from the target sequence, by competing with a common
site on the DNA.
MGBs inhibit DA and DAB complex formation
We then performed dose-response inhibition experiments on the
DA complex, similar to the ones described before for the
TBP-TATA complex. At low concentrations (10 ng) hTBP does
not bind DNA in a detectable way (Fig. 4A, lane 1), neither does
partially purified TFIIA from HeLa cells (lane 2), however, when
hTBP and TFIIA were mixed together the DA complex was
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Figure 3. Inhibition of TBP-TATA interaction by distamycin A and tallimus-
tine. (A) The AdML oligonucleotide was first incubated with increasing
concentrations of the indicated drug and then 2 ng yTBP (labeled P in the
scheme) was added and further incubated for 30 min. (B) yTBP and the AdML
oligonucleotide were incubated before addition of the indicated amount ofeach
drug. (C) As (B) except that 500 ng hTBP was used.
visible (lane 3). Another faster migrating complex was apparent
on these gels and is due to non-specific interactions of a
contaminant present in the TFIIA fraction (labeled NS; see
28-30). Results of inhibition experiments are shown in Figure 4A
(lanes 4-11): a 10-fold higher dose ofMGB drugs was necessary
to inhibit binding with respect to the hTBP-TATA complex, best
evidenced from the lack of inhibition at 200 nM. A slightly
different picture was revealed when we changed the order of
addition; formation of the DA complex before addition of either
distamycinA or tallimustine yielded a reduction (80%) only at the
highest (20 ,uM) dose (Fig. 4B, lanes 4-11). It should be noted that
in the experiments in Figure 4, the non-specific complex (NS) is
unaffected even at 20 FM, confirming that the two MGB drugs
only act on sequence-specific proteins.
We next added to the system recombinant TFIIB, another
essential component of the pre-initiation complex known to
stabilize the binding ofTBP toDNA (26,27). Figure 5 shows that
addition of TFIIB to the DA complex results in the formation of
a new complex (DAB) of slower electrophoretic mobility (Fig.
SA and B, lanes 1 and 2). When the DAB complex was first
formed and then challenged with MGBs, inhibition was observed
im 4W. ot^-
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Figure 4. Inhibition of the DA complex by distamycin A and tallimustine. (A)
EMSA of AdML TATA oligonucleotide with 10 ng hTBP (lane 1) or 0.5 gl
partially purified TFIIA (lane 2). The same amount ofhTBP and TFIIA together
with (lanes 4-11) or without (lane 3) increasing amounts of the indicated drug.
(B) As (A) except that the MGBs were added after DA complex formation (see
scheme).
only at a 20FM concentration of distamycin and hardly at all with
tallimustine. In the opposite experiment, the picture was similar
to that observed with the DA complex, with the exception of a
lack of inhibition at 2 ,uM tallimustine (Fig. 5A, lane 9).
Interestingly, low concentrations of both drugs reproducibly
increased the binding of the DAB complex to DNA (compare
lanes 2 and 3, 4, 7 and 8 in Fig. 5A and B).
We can conclude that TFIIA and TFIIB, by stabilization of the
TBP-TATA interaction, can efficiently prevent displacement by
the MGBs, whereas both distamycin A and tallimustine are still
efficient at inhibiting binding of the DA and DAB complexes.
MGBs inhibit in vitro transcription
It has been well established that TBP is absolutely required for
promoter recognition by all three RNA polymerases (25). Genetic
and biochemical analysis of several TATA-containing promoters
indicate that TBP recognition of the TATA box is the primary
event in the formation of the pre-initiation transcription complex
(25-27). Since this interaction can be inhibited by distamycin A
and tallimustine, we wished to verify whether they could be
detrimental to the process of transcriptional activation. It is not
known, in fact, whether an initiation complex, which binds tightly
and stably to a promoter, can be perturbed by such compounds nor
whether they can interfere with Pol II elongation.
For this purpose we used the in vitro transcription system that
we have recently developed (31,33), adapted to a minimal
TATA-containing promoter. It consists ofhuman erythroid K562
nuclear extracts transcribing a 3-globin reporter gene under the
control of a minimal P-globin promoter, pAL5, containing up to
nucleotide -41, thus being devoid of any upstream activating
sequences and absolutely dependent both on the TATA box and
on the presence of TBP (30,32). Only basal transcription can be
Figure 5. Inhibition of the DAB complex by MGBs. (A) EMSA of AdML
TATA box oligonucleotide with 10 ng hTBP and 0.5 RI TFIIA (lane 1) or 20 ng
recombinant TFHB without MGBs (lane 2) or with increasing concentrations
of both drugs (lanes 3-10). DNA was first incubated with MGBs. (B) As (A)
except that MGBs were added after DAB complex formation.
scored with this construct (42). Finally, this promoter contains no
otherDNA stretch that might be susceptible toMGB binding (see
sequence in Materials and Methods). Upon incubation of the
template DNA with the nuclear extract and addition of nucleo-
tides, transcription ensues and continues for multiple rounds over
a 40 min period (31,43-45). The resulting RNA is purified and
analyzed by S1 mapping, using a single-stranded, end-labeled
DNA probe (34). Two signals are expected from this basal
promoter: the correct P-globin +1 and a RT signal coming from
spurious weak start sites along the vector. The latter is expected
to be strong, since the system is devoid of any upstream activator
that will focus the transcriptional machinery on the TATA box.
We first wanted to verify whether MGBs might have a general
negative effect on transcriptional initiation or elongation. We thus
exploited the fact that in a number of systems, including ours,
incubation of extracts with the template DNA leads to the rapid
formation (over a period of 15 min) of a pre-initiation complex
that is fully competent for transcription and is resistant to
Sarkosyl, competing oligonucleotides and antibodies
(31,4345). We pre-incubated pAL5 with the K562 extract first,
so that a competent pre-initiation complex is formed; then we
added the drugs at different concentrations. It should be noted that
the amount ofplasmid used is comparable in molar terms with the
amount of TATA oligonucleotide used in the EMSA. Figure 6
shows that no significant decrease in either spurious RT
transcripts or the correct +1 signal was observed, indicating that
the transcription complex on the promoter is quite resistant to
MGB challenge. Therefore, lack of transcriptional repression
rules out direct negative effects that the drugs might have on the
proteins of the transcriptional apparatus or on the elongation
process.
Similarly, we performed experiments changing the order of
addition of the components. We pre-incubated template DNA
with increasing concentrations of both MGB drugs before
addition of the transcription extract and NTPs, according to the
scheme depicted in Figure 7. A clear inhibition of the specific +1
signal was already evident with both drugs at 2 gM.
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Figure 6. Effect of distamycin A and tallimustine on in vitro transcription after
pre-initiation complex formation. The pAL5 template DNA containing a
minimal ,B-globin promoter was first incubated with K562 nuclear extract after
which drugs were added at different concentrations and incubation continued;
nucleotide (NTPs) addition started transcription, which was stopped after 40
min. RNA was purified, hybridized and analyzed by SI mapping. The sample
in lane I is the control with no drug. RT is read-through transcription starting
from spurious upstream vector sequences, while + I corresponds to the correctly
initiated j-globin signal.
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Figure 7. Inhibition of in vitro transcription by distamycin A and tallimustine.
The transcription read-out of the experiment is as in Figure 6, except thatMGBs
were incubated with the template pAL5 DNA before addition of the
transcription extract and nucleotides (NTPs). Samples were treated as in the
experiments in Figure 6.
Surprisingly though, while at 20 jM distamycin A the RT
transcripts were decreased, at 20 ,uM tallimustine the RT signal
is at normal levels: the ratio between RT and +1 transcription
increases considerably from 200 nM to 20 ,uM (see Fig. 7, lanes
5-7). We conclude that distamycin A has a specific effect on the
+1 signal, best seen at 2 jM, and a more non-specific one at 20
,uM (inhibition of RT transcription coming from spurious start
sites in the vector), but tallimustine only shows a specific
inhibition of the f-globin promoter over the three concentrations.
This finding reinforces the notion that there is no general
inhibitory activity on the transcriptional apparatus or on Pol II
progression.
DISCUSSION
In this study we evaluated the inhibitory effects of the MGBs
distamycin A and the alkylating derivative tallimustine on the
interactions between the general transcription factors TBP, TFIIA
and TFIIB and their target TATA box sequence, in terms of both
DNA binding and transcriptional activation.
The oligonucleotide that we used contained no other possible
binding site for these two drugs but the sequence TATAAAA,
which is recognized by TBP (39-41), and specificity for AT-rich
sequences was confirmed by lack of competition on SP1. A
possible direct negative effect of the two compounds on
recombinant TBP is ruled out by MGB-TBP binding experi-
ments. Moreover, yTBP and hTBP concentrations necessary to
shift the TATA oligonucleotide differed considerably, yet inhibi-
tory doses follow apparent DNA binding affinity (yTBP > hTBP)
and not protein concentration (hTBP > yTBP). We can conclude
that direct competition for a common recognition sequence is thus
responsible for the binding data presented.
Several points can be made. (i) Both yTBP and hTBP alone are
susceptible to >90% inhibition by the drugs at concentration of 2
,uM, a result in good agreement with the study of Chiang et al.
(17), who found that the concentration ofdistamycin A necessary
to produce 50% inhibition ofthe hTBP-TATA complex is 160nM
and complete inhibition was observed at 1 ,uM. Higher concentra-
tions (10-fold) were reported to be necessary to inhibit DNA
binding of the Antp homeodomain (16), OTFI and GATA1 (15).
(ii) Both drugs shows very similar dose-response curves when
changing the order of addition, indicating that MGBs can
interfere not only with TBP-DNA interactions, but can also
displace the complex once it is formed. This is somewhat
surprising, considering that the yTBP-TATA complex has been
shown to have a very slow dissociation rate, with a half-life of >1
h (46). However, the same kinetic studies suggested that binding
of yTBP to the TATA box is a multi-step process, which would
help explain the data presented here. If one (or more) less stable
intermediate(s) is formed, it is conceivable that it might still be
attackable by MGBs, shifting the equilibrium toward dissociation
of the complex(es). Interestingly, co-crystals of TBP and the
TATA box have indicated that the underside concave surface of
TBP makes direct hydrophobic interaction with a widened
AT-containing minor groove: this will represent the working
model to understand MGBs displacment activity. (iii) The effects
of MGBs on the DA and DAB complexes are rather different.
While inhibition was still evident on pre-incubating the DNA and
the drugs first, if the DA and DAB complexes are first formed,
displacement can be observed only at much higher MGB
concentrations (20- and 100-fold). In the study of Chiang et al.,
addition of yeast TFHA before drug challenge also led to a
stabilization of the TBP-TATA complex, while the reverse
experiment was not tried (17). The higher drug concentrations
required in our study are probably due to the different experi-
mental conditions: (a) in our assays free DNA was always in large
excess (no more than 5-15% ofthe oligonucleotide is shifted); (b)
we have used hTFIIA (as opposed to yeast); (c) a longer TATA
oligonucleotide (37mer versus 24mer). It is known that addition
of hTFIIA extends the TBP footprints of TATA elements
(36,37,47,48), suggesting that flanking sequences somewhat
stabilize the DNA-protein interactions.
These data are in agreement with previous observations on the
stabilizing role of TFIIA and TFIIB in promoter recognition by
TBP (47,48). The remarkable resistance of pre-formed DA and
DAB complexes described here suggests that TFIIA, by binding
to the TBP-DNA complex, might somehow shield access to the
minor groove of MGBs. CC1065, another sequence-specific
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MGB able to alkylate adenine N3, also behaves in a similar way
(see 17; data not shown).
In these DNA binding interference studies no striking differ-
ence between distamycin A and tallimustine was obvious, except
that slightly higher doses (2-fold) of the latter were consistently
necessary for inhibition under all conditions tested. This behavior
might be related to a lower affinity for DNA in general or to a
more pronounced sequence specificity of tallimustine, which
indeed has been shown to preferentially alkylate the A in the
sequence TTTTTGA or the second A in TlTIlAA (8,9).
The functional in vitr transcription experiments shown here
represent the first evidence that MGBs are able to alter the
transcription rate of a promoter, by interfering with TBPiTFIID
binding.
Several lines of data lead to this conclusion. (i) We used a
minimal promoter containing only the P-globin TATA box; this
sequence is surrounded by a GC-rich area, which could not be
bound by MGBs of the distamycin A family. For the relatively low
levels of basal tanscription the TATA box is essential (19,42). (ii)
The doses of both drugs necessary for DA/DAB-TATA inhibition
parallel well the doses that are inhibitory in the transcription
system. (iii) It is sufficient to pre-incubate the extract with the
template DNA, under conditions that allow pre-initiation complex
to form, to essentially abolish the inhibitory effect. The two drugs
do not affect elongation of either the correct +1 signal or the
spurious RT transcripts, even at high doses, implying that it is not
by obstructing RNA Pol H progression or the elongation complex
in general that the inhibitory effect is brought about. Thus these
compounds are unlikely to represent general non-specific inhibi-
tors of transcription.
It is believed that in living cells (and consequently in nuclear
extracts) TBP is tightly complexed with several TAFs (TBP
associated factors), forming TFIID complexes (25). Inhibition of
basal in vitro transcription byMGBs suggests that they also prevent
binding of TFIID to DNA, which is not too surprising, since TBP
represents the major TATA-contacting moiety of the complex. The
affinity ofMGBs for DNA is far lower than that ofTBP alone (Kd
values are 10-7 and IO-9 respectively) and it should be considered
that the other components of the initiation complex, TF1IA, TFIIB
and the TAFs in particular, will further increase the difference, by
stabilizing TBP on the TATA box and making contacts with
neighbouring sequences. In addition, our system allows multiple
rounds of re-initiation (31,33): we find it remarkable that these
drugs, despite the difference in affmity, are able to resist the
challange ofthe general transcription machinery and that inhibition
is not limited to the first round, but remains strong over the
transcription reaction, suggesting that MGB-TATA interactions
cannot be easily displaced by transcriptional factors.
Perhaps the most surprising result in this study is that, unlike
distamycin A, tallimustine only showed inhibition of the correct
+1 signal, even at high concentrations. From the binding studies
one could in fact anticipate that tallimustine would require higher
concentrations to achieve the dystamicin A inhibitory effect.
While distamycin A showed inhibition at lower doses for +1 than
for RT 'non-specific' transcription, the tallimustine response was
slower, but much more specific. These data can be explained by
considering the higher affinity of distamycin A for AT sequences,
also demonstrated by the binding studies, and the fact that
tallimustine contacts two additional nucleotides (9). The require-
ment for additional nucleotides might confer a higher sequence
selectivity to the latter drug, which would have fewer or no other
target sequences on the plasmid in addition to the TATA box in the
minimal promoter and hence be less effective in inhibition ofRT
transcription. This might also be indirectly suggested by the
already mentioned tallimustine selective alkylation pattern (8,9).
Although these observations do not prove directly that MGBs
do interfere with transcription in vivo, they could give important
indications of the potential mechanisms of action of MGBs, still
largely unknown. Pre-initiation and initiation complexes are
stable in vivo and are believed to be displaced byDNA replication
events (49). The resistance of the pre-initiation complex to
inhibition by MGBs even at high concentrations is not surprising,
in the light of their remarkable stability once bound to promoter
sequences. This observation suggests that MGB activity in vivo
is unlikely to be related to perturbation of ongoing transcription
and that they need naked DNA to bind to essential regulatory
elements. Thus the activity of MGBs in vivo could be limited to
a certain phase of the cell cycle, when the DNA is replicated and
becomes a possible target for these drugs. We favor a model in
which MGBs and transcription factors compete for a specific
DNA sequence and it would be a matter of affinity and
concentration of the two competitors to determine which first
recognizes a given regulatory element. In this scenario it is
conceivable that alkylating agents such as tallimustine (or
CC 1065), being covalently anchored to specific DNA sequences,
although no more prompt to stably occupy available sites than
distamycin A, are more prone to resist the challenge of
transcription factors. Although the vast majority of sequence-
specific DNA binding proteins contact DNA through the major
groove, the set of experiments presented here is intended to
indicate that the TATA box is only one of the possible targets of
these drugs. Certainly, many other important regulatory proteins
recognizing AT-rich sequences could be potential targets for these
molecules: inhibition of binding of CCAAT-box binding protein
NF-Y (CPI-CBF) by MGBs appears to be highly dependent on
neighbouring sequences (A. Ronchi, in preparation).
We are confident that the functional assay described here will
be an important tool in elucidation of the molecular mechanisms
underlying the action of these drugs, as we have started to perform
here, and in the screening of new highly selective sequence-
specific compounds.
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